MiMARK is developing WomEC, an in vitro diagnostic immunoassay that utilizes a panel of five protein biomarkers in uterine fluids to accurately detect endometrial cancer, achieving 99% sensitivity and 79% specificity. This approach addresses the limitations of traditional endometrial biopsies, which fail to diagnose 31% of patients and often require invasive procedures like hysteroscopy.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing endometrial cancer, such as endometrial biopsies, have limitations, including a failure to diagnose a significant percentage of patients and the need for invasive procedures like hysteroscopies in some cases. These biopsies, relying on cellular material, can provide inaccurate diagnoses due to scarce cellularity in the sample.
Solution
MiMARK is developing WomEC, an in vitro diagnostic immunoassay designed to improve the accuracy and efficiency of endometrial cancer diagnosis. WomEC utilizes a panel of five protein biomarkers found in uterine fluids, rather than relying on cellular material. This approach allows for a highly accurate diagnosis with reported sensitivity of 99 percent and specificity of 79 percent. The immunoassay format is intended to facilitate implementation in clinical laboratories, providing clinicians with an objective diagnostic tool.
Target Audience
The primary target audience includes gynecologists, pathologists, and clinical laboratories involved in the diagnosis and management of endometrial cancer.
Features
- Immunoassay test based on the quantification of five protein biomarkers in uterine fluid.
- High sensitivity (99%) and specificity (79%) for endometrial cancer detection.
- Designed to be less invasive, potentially reducing the need for hysteroscopies.
- Provides information regarding tumor classification for treatment planning.
- Aims to reduce diagnosis time from one month to two days.